Tarsus Pharmaceuticals (TARS) Accounts Payables (2023 - 2026)

Tarsus Pharmaceuticals' Accounts Payables history runs 4 years deep, the most recent figure standing at $24.1 million for Q1 2026.

• On a quarterly basis, Accounts Payables changed N/A year-over-year to $24.1 million in Q1 2026; TTM through Mar 2026 was $24.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $16.4 million, up 73.98% from the prior year.
• Accounts Payables grew to $24.1 million in Q1 2026 per TARS's latest filing, from $16.4 million in the prior quarter.
• Across five years, Accounts Payables topped out at $24.1 million in Q1 2026 and bottomed at $400000.0 in Q1 2023.
• The 4-year median for Accounts Payables is $12.9 million (2024), against an average of $12.6 million.
• Biggest YoY gain for Accounts Payables was 73.98% in 2025; the steepest drop was 73.98% in 2025.
• Year by year, Accounts Payables stood at $400000.0 in 2023, then surged by 2254.75% to $9.4 million in 2024, then jumped by 73.98% to $16.4 million in 2025, then soared by 47.26% to $24.1 million in 2026.
• Per Business Quant, the three latest TARS Accounts Payables figures stand at $24.1 million (Q1 2026), $16.4 million (Q4 2025), and $9.4 million (Q4 2024).